ASCO Annual Meeting

Abhishek Maiti, MD, discussed the EVICTION trial in AML and results presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a manageable safety profile.

In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual Meeting.

Higher pretreatment HER2 amplicon mRNA and HER2 protein levels predicted improved time to next treatment with T-DXd in metastatic breast cancer. Conversely, higher TOPO1 protein correlated with worse outcomes.

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and progression-free survival in recent clinical trials.

Adding cobolimab to dostarlimab as neoadjuvant treatment for high-risk resectable melanoma improved major pathological response rates and was tolerable.

Undetectable ctDNA at cycle 6 strongly predicts reduced progression/death risk in locally advanced cervical cancer patients treated with durvalumab/CRT or CRT alone.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

A single cilta-cel infusion led to 33% of heavily pretreated relapsed/refractory multiple myeloma patients remaining progression-free at 5+ years.

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ovarian cancer, warranting further study.

Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response rates in intermediate-to-high-risk prostate cancer.

Alicia Morgans, MD, MPH, discusses the phase 3 ARASTEP trial evaluating darolutamide in patients at high risk of biochemical recurrence of prostate cancer.

Ziftomenib shows promising results in treating relapsed/refractory NPM1-mutant AML, achieving significant remission rates and a favorable safety profile.

Neoadjuvant nivolumab plus chemotherapy significantly improves overall survival in resectable non-small cell lung cancer, marking a treatment breakthrough.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

The ongoing ARASTEP trial evaluates darolutamide plus ADT vs placebo for high-risk prostate cancer biochemical recurrence with PSMA PET-CT-positive lesions, aiming to improve rPFS.

Lifileucel therapy shows promising long-term survival and response rates in advanced melanoma patients, offering hope for those with limited treatment options.

Olaparib and radium-223 bested radium-223 alone in radiographic progression-free survival in men with castration-resistant prostate cancer.

Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical cancer.

Meghan Mooradian, MD, discusses findings and implications of the phase 2 NEO-MEL-T study.

Darolutamide significantly delayed pain progression and improved overall well-being in patients with metastatic hormone-sensitive prostate cancer.

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in high-risk locally advanced cervical cancer, establishing a new standard of care.

The FIRST/ENGOT-OV44 trial found dostarlimab plus platinum-chemo and niraparib maintenance modestly improved PFS (20.6 vs 19.2 months) in advanced ovarian cancer, with expected safety.

DeLLphi-304 trial results showed tarlatamab significantly improved PFS and OS over chemotherapy in second-line SCLC, establishing it as a new standard.

A prophylactic dermatologic regimen significantly reduced skin side effects and improved quality of life for NSCLC patients on amivantamab/lazertinib.

Benmelstobart alone or with anlotinib improved progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.